AU Patent

AU2020336272A1 — Thyroid hormone receptor beta agonist compounds

Assigned to Terns Pharmaceuticals Inc · Expires 2022-04-14 · 4y expired

What this patent protects

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

USPTO Abstract

Provided herein are compounds, preferably thyroid hormone receptor beta (THR beta) agonist compounds, compositions thereof, and methods of their preparation, and methods of agonizing THR beta and methods for treating disorders mediated by THR beta.

Drugs covered by this patent

Patent Metadata

Patent number
AU2020336272A1
Jurisdiction
AU
Classification
—
Expires
2022-04-14
Drug substance claim
No
Drug product claim
No
Assignee
Terns Pharmaceuticals Inc
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.